je.st
news
Tag: biosimilar
First Biosimilar Drug Now Available; Ongoing Legal Dispute Remains
2015-09-05 03:32:12| Biotech - Topix.net
The first biosimilar is now available in the United States. Sandoz announced the availability of Zarxio earlier today, after the Federal Circuit denied Amgen Inc.'s attempt to stall the launch.
Tags: legal
drug
remains
ongoing
Novartis launches first US 'biosimilar' drug at 15 percent discount
2015-09-03 23:44:28| Biotech - Topix.net
Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first "biosimilar" copy of a biotechnology drug approved in the United States, at a discount of 15 percent to the original. The Swiss drugmaker's generics unit Sandoz said Zarxio, its form of Amgen's white blood cell-boosting product Neupogen, would increase access to an important treatment by offering a "high-quality, more affordable version".
Tags: drug
percent
discount
launches
Rapid Development And Scale Up Of A Biosimilar
2015-07-16 07:51:26| drugdiscoveryonline Home Page
Increasing and competitive market of Biosimilars requires a rapid platform from cell line development to process development and scale-up to manufacturing.
Tags: development
scale
rapid
rapid development
Exclusive: Hospira Wins French Biosimilar Drug Tender At 45 Percent Discount
2015-07-04 01:46:09| Biotech - Topix.net
A major French hospital group has chosen a cheap copycat version of a top-selling drug for treating its patients with rheumatoid arthritis, Crohn's disease and psoriasis in a victory for a new type of medicine known as biosimilars. In a document seen by Reuters, the central purchasing agency for the Assistance Publique - HA pitaux de Paris said on Friday it had decided to buy the biosimilar version of infliximab from Hospira, after the company offered a discount of some 45 percent to branded Remicade.
Tags: french
drug
percent
discount
Federal Circuit Keeps Sandoz Biosimilar Off the Market for Now
2015-05-08 04:19:44| Biotech - Topix.net
The Federal Circuit is set to hear oral arguments in Amgen v. Sandoz on June 3, but in the meantime has granted Amgen's motion for a preliminary injunction to keep Sandoz' biosimilar version of Neupogen off the market until it renders its decision.
Tags: now
market
federal
circuit